Neutropenia occurs when an individual has low levels of neutrophils, a type of white blood cells. Neutrophils are made in the bone marrow, which is the spongy tissue found in larger bones such as the vertebrae, ribs, and pelvis. White blood cells support the body in fighting infections. Neutrophils fight against infection by demolishing harmful fungi, yeast, and bacteria that attack the body. People with neutropenia have a higher risk of developing serious infections. Half of the individuals with cancer who receive chemotherapy develop some level of neutropenia. Neutropenia is a common side effect in people living with leukemia.
The global neutropenia treatment market is anticipated to expand rapidly in the near few years. Introduction of novel therapies and increase in the cases of chemotherapy-induced neutropenia are likely to be major drivers of the neutropenia treatment market. Cancer is a known cause for developing neutropenia. A rise in the cases of chemotherapy for the treatment of cancer is projected to boost the neutropenia treatment market. Cancer is among the top five causes of death across all age groups around the world. In 2014, about 1.6 million new cases of cancer were registered in the U.S., and approximately 600,000 individuals died due to the disease. The most common cancers are prostate cancer, cervical cancer, ovarian cancer, leukemia, pancreatic cancer, lung cancer, breast cancer, non-Hodgkin lymphoma, colorectal cancer, and Hodgkin’s disease. Many of these cancers are curable, particularly when treated at early stages. However, most of them are fatal without treatment.
Novel products such as Taiho Pharmaceutical’s drugs, ZOSYN 2.25, ZOSYN 4.5 for I.V. infusion bag and ZOSYN 4.5, are in the pipeline. In 2015, these products received marketing authorization for the treatment of febrile neutropenia in Japan. These products are expected to reform the global neutropenia market. Some key players are taking initiatives to increase awareness about these new mechanisms among healthcare professionals. This is expected to fuel the market. Additionally, novel drug delivery methods are improving patient convenience, which is leading to improved patient adherence, thus propelling the neutropenia treatment market. For instance, in April 2017, Amgen launched the new Neulasta (Pegfilgrastim) Delivery Kit. This kit is a novel drug delivery method that allows self-administration of Neulasta, which helps stimulate the production of white blood cells.
The global neutropenia treatment market can be segmented based on treatment, distribution channel, and region. In terms of treatment, the neutropenia treatment market can be categorized into antibiotics, granulocyte -colony- stimulating factor (G-CSF), and antifungal drugs. The granulocyte -colony- stimulating factor (G-CSF) segment is expected to account for a prominent market share and expand at a moderate pace during the forecast period. A rise in the utilization of granulocyte -colony- stimulating factor agents in stimulating the creation of granulocyte is expected to propel the segment. Based on distribution channel, the global neutropenia treatment market can be classified into retail pharmacies, hospital pharmacies, and online pharmacies.
Based on region, the global neutropenia treatment market can be segmented into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is projected to lead the global market during the forecast period. The region’s dominance is attributed to an increase in demand for therapeutic needs for febrile neutropenia and execution of new regulations for the commercialization and development of biosimilars. The neutropenia treatment market in Asia Pacific is anticipated to expand at a rapid pace during forecast period, due to a rise in the prevalence of different forms of cancer and increase in health care awareness.
Key players operating in the global neutropenia treatment market are Baxter International, Teva Pharmaceutical, Inc., Amgen, Sanofi, Novartis AG, Teva, Pharmaceuticals Industries Ltd, Biogenomics Limited, Dr. Reddy’s Laboratory Ltd., Apotex, and Intas Pharmaceuticals Ltd.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.
TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.
Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:
Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.
Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.
Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.